105963-46-0
| 中文名称 | 105963-46-0 |
|---|---|
| 中文同义词 | 化合物 T13180;化合物 TOK-8801 |
| 英文名称 | TOK 8801 |
| 英文同义词 | TOK 8801;Imidazo[2,1-b]thiazole-2-carboxamide, 5,6-dihydro-3,6,6-trimethyl-N-(2-phenylethyl)-;TOK 8801,TOK8801;3,6,6-trimethyl-N-(2-phenylethyl)-5H,6H-imidazo[2,1-b][1,3]thiazole-2-carboxamide |
| CAS号 | 105963-46-0 |
| 分子式 | C17H21N3OS |
| 分子量 | 315.439 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 105963-46-0.mol |
| 结构式 |  |
105963-46-0 性质
| 密度 | 1.23±0.1 g/cm3(Predicted) |
|---|---|
| 储存条件 | Store at -20°C |
| 溶解度 | 溶于二甲基亚砜 |
| 酸度系数(pKa) | 13.27±0.40(Predicted) |
TOK-8801 is a synthesized dihydroimidazothiazole carboxamide and is under development as an immunomodulator. TOK-8801 augments the in vitro anti-SRBC PFC response of murine splenocytes in a bell-shaped manner. The stimulatory effect of TOK-8801 is observed at concentrations of 2.5×10 -7 to 2.5×10 -5 M and is diminished at 10 -4 M. The cell-viability is not altered during the culture with TOK-8801 at any doses used in this experiment (10 -7 to 10 -4 M). TOK-8801 enhances the 3 H-TdR uptake of these responses in a bell-shaped manner, and effective concentrations of TOK-8801 are 10 -7 to 10 -5 M.
The anti-SRBC PFC response per spleen, which is prominently lowered by restraint-stress (P<0.05), is significantly restored by the administration of TOK-8801 (0.5 mg/kg, P<0.05). The number of total splenic lymphocytes in restraint-stress is decreased, but there are no significant changes in the number of total splenic lymphocytes by the treatment with TOK-8801. When TOK-8801 is administered orally at doses of 0.1 to 10 mg/kg, the number of plaque forming cell (PFC) significantly decreases or tends to decrease. Treatment of TOK-8801 at doses of 0.1 to 1 mg/kg causes significant suppression in the delayed-type hypersensitivity (DTH) reaction induced in high responder.